BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 28
• 29
• 30
• 31

• Drug Development

  Celgene Release: Study Of Bortezomib Added To Revlimid And Dexamethasone Backbone Therapy Presented At American Society of Hematology

  December 7, 2015

   · 

  20 min read
• Drug Development

  GlycoMimetics, Inc. Presents At American Society of Hematology Meeting First-In-Human Data Showing Favorable Safety, Metabolic And Biomarker Profiles For GMI-1271

  December 7, 2015

   · 

  4 min read
• Drug Development

  Johnson & Johnson Announces Completion Of Novira Therapeutics Acquisition

  December 7, 2015

   · 

  3 min read
• Drug Development

  GlycoMimetics, Inc. Poster Shows GMI-1271 Reverses Drug Resistance In Multiple Myeloma Models

  December 7, 2015

   · 

  3 min read
• Drug Development

  Sunesis Announces Presentation Of Positive Results From MD Anderson Cancer Center Sponsored Trial In AML At American Society of Hematology Annual Meeting

  December 7, 2015

   · 

  6 min read
• Drug Development

  Sunesis Announces Presentation Of Results From Washington University Sponsored Phase 1/2 Trial Of Vosaroxin In MDS And VALOR Analysis Of Baseline Safety Predictors At Washington University Annual Meeting

  December 7, 2015

   · 

  7 min read
• Drug Development

  Incyte Release: Phase 3 RESPONSE-2 Study of Jakafi (ruxolitinib) Meets Primary Endpoint

  December 7, 2015

   · 

  7 min read
• Drug Development

  Incyte Release: Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi (Ruxolitinib) In Patients With Myeloproliferative Neoplasms(MPNs)

  December 7, 2015

   · 

  12 min read
• Adaptive Biotech’ clonoSEQ MRD Test Can Be Used To Guide Post-Transplant Treatment Decisions In Multiple Myeloma Patients

  December 7, 2015

   · 

  4 min read
• Drug Development

  Bristol-Myers Squibb Release: New Longer-Term Data For Empliciti (Elotuzumab) Showed A Continued Progression-Free Survival Benefit In Patients With Relapsed Or Refractory Multiple Myeloma

  December 7, 2015

   · 

  12 min read